Validating a Wearable-Derived Endpoint
The verification, analytical validation and clinical validation steps behind a digital endpoint.
Tomasz Nowak
Northwind Scientific Instruments
Lower Is Better? Revisiting LDL Targets After the Latest Outcome Trials
A review of this year’s lipid-lowering outcome data and the revised regional targets.
Amara Okafor
Harbour City Hospital
Mapping Tissue-Resident Immunity at Single-Cell Resolution
What a national immune atlas has revealed about tissue-resident cells in health and disease.
Mei Chen
Pacific Genomics Centre
GLP-1 Receptor Agonists in the Cardiology Clinic
Who to start, who to refer and how to monitor, from a clinic that has prescribed them for three years.
Amara Okafor
Harbour City Hospital
Decentralised Trials: What Changed After the Pandemic
Which remote trial practices stayed, which were abandoned, and why.
Rachel Goldberg
Independent
Paying for Precision: The Economics of Molecular Testing
Where molecular testing saves money, where it does not, and how payers decide which is which.
Kwame Mensah
Meridian Life Sciences Society
Real-World Evidence From the Reviewer’s Chair
Common reasons real-world submissions fail review, and how to avoid them.
Rachel Goldberg
Independent
Pre-emptive Pharmacogenomic Testing Across Three Hospitals
Uptake, alerts fired and prescribing changes in the first two years of a pre-emptive panel.
Liam O’Connell
Meridian Research Institute
Running a Platform Trial: Five Lessons From the First Three Arms
Operational and statistical lessons from adding and dropping arms in a running platform trial.
Daniel Reyes
Southern Cross Clinical Trials Unit
Decision Support That Prescribers Do Not Ignore
Designing genotype alerts that change prescribing rather than adding to alert fatigue.
Liam O’Connell
Meridian Research Institute
Shorter Antibiotic Courses: The Evidence and the Pushback
Trial evidence for shorter courses in common infections, and how to bring prescribers with you.
Fatima Al-Sayed
Gulf Children’s Hospital
Is Pre-emptive Genotyping Worth It?
A cost-effectiveness model built from the programme’s own prescribing data.
Kwame Mensah
Meridian Life Sciences Society
What Regulators Look for in an Adaptive Design
Type I error control, pre-specification and the documentation that makes an adaptive design reviewable.
Rachel Goldberg
Independent
Rapid Diagnostics as a Stewardship Tool
How faster pathogen identification changes empirical prescribing on the ward.
Fatima Al-Sayed
Gulf Children’s Hospital
From Atlas to Target: Choosing What to Engineer
Using single-cell reference maps to select antigens for engineered cell therapies.
Elena Rossi
Istituto di Medicina Traslazionale
Nurse-Led Follow-Up After a Cardiac Event
Outcomes from a nurse-led secondary prevention programme across four regional hospitals.
Sarah Whitfield
Coastal Health District
RSV and Influenza Surveillance in Children, 2023–2026
Regional surveillance data on timing, severity and the effect of new RSV immunisation.
Fatima Al-Sayed
Gulf Children’s Hospital
Shortening Vein-to-Vein Time in CAR-T Manufacturing
Process changes that cut manufacturing time from three weeks to nine days without losing potency.
Elena Rossi
Istituto di Medicina Traslazionale
Judging the Credibility of a Subgroup Effect
A checklist for reading subgroup claims, applied to five recent trials.
Daniel Reyes
Southern Cross Clinical Trials Unit
Planning Paediatric Surge Capacity
How a children’s hospital planned beds, staff and antimicrobials for a peak winter.
Fatima Al-Sayed
Gulf Children’s Hospital
Outcomes-Based Agreements for One-Off Therapies
How instalment and outcomes-based payment models are being written for curative therapies.
Kwame Mensah
Meridian Life Sciences Society
Treatment Heterogeneity and Machine Learning: Promise and Caution
What causal machine-learning methods can add to subgroup analysis, and where they mislead.
Tomasz Nowak
Northwind Scientific Instruments
Circulating Tumour DNA as a Guide to Adjuvant Therapy
What serial ctDNA testing adds after surgery, and where its negative predictive value is still too weak to withhold treatment.
Priya Raman
Tasman University Medical School
Building a Nurse-Led Heart Failure Service
Readmission and quality-of-life outcomes from a nurse-led heart failure network.
Sarah Whitfield
Coastal Health District
From Registry to Label Extension: A Worked Example
The design choices behind a registry-linked study that supported a label extension.
Hiroshi Sato
Kansai Clinical Outcomes Network
Biomarker-Stratified Trials That Actually Answer the Question
Enrichment, stratification and adaptive designs compared against the questions clinicians bring to them.
Daniel Reyes
Southern Cross Clinical Trials Unit
Telehealth Titration in Type 2 Diabetes
Remote insulin and GLP-1 titration delivered by nurse practitioners over twelve months.
Sarah Whitfield
Coastal Health District